Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.

[1]  T. H. van der Kwast,et al.  A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. , 2019, European urology.

[2]  T. H. van der Kwast,et al.  Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up. , 2019, European urology.

[3]  A. Kibel,et al.  Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. , 2019, European urology.

[4]  A. D'Amico,et al.  Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015 , 2019, JAMA.

[5]  P. Albers,et al.  Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. , 2019, European urology.

[6]  L. Holmberg,et al.  Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up , 2018, New England Journal of Medicine.

[7]  P. Ström,et al.  Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. , 2018, European urology.

[8]  Eric A. Miller,et al.  Extended follow‐up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial , 2018, BJU international.

[9]  A. Gavin,et al.  Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.

[10]  Raj Persad,et al.  A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer , 2018, European urology.

[11]  Thomas Agoritsas,et al.  Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis , 2018, British Medical Journal.

[12]  F. Montorsi,et al.  Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. , 2018, European urology.

[13]  R. Stoyanova,et al.  Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer , 2018, PloS one.

[14]  H. G. van der Poel,et al.  Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. , 2018, European urology.

[15]  J. Gore,et al.  PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening , 2018, Cancer.

[16]  A. Vickers,et al.  Value of a Statistical Model Based on Four Kallikrein Markers in Blood, Commercially Available as 4Kscore, in All Reasonable Prostate Biopsy Subgroups. , 2018, European urology.

[17]  A. Rosenkrantz,et al.  The Institutional Learning Curve of Magnetic Resonance Imaging‐Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years , 2018, The Journal of urology.

[18]  Douglas K Owens,et al.  Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[19]  H. Bang,et al.  Prostate-Specific Antigen–Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.

[20]  P. Prorok,et al.  Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials , 2018, Annals of Internal Medicine.

[21]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[22]  E. Feuer,et al.  The efficacy of prostate‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials , 2018, Cancer.

[23]  J. Sterne,et al.  Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial , 2018, JAMA.

[24]  A. Kader,et al.  Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice. , 2017, Urologic oncology.

[25]  E. Feuer,et al.  Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials , 2017, Annals of Internal Medicine.

[26]  H. G. van der Poel,et al.  Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. , 2017, European urology focus.

[27]  T. H. van der Kwast,et al.  Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. , 2017, European urology.

[28]  John T. Wei,et al.  Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer , 2017, BJU international.

[29]  M. Roobol,et al.  Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging? , 2017, European urology.

[30]  T. Lehtimäki,et al.  A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale , 2017, European Journal of Epidemiology.

[31]  Jason D. Wright,et al.  Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States , 2017, JAMA oncology.

[32]  Andrew K. Moriarity,et al.  Prostate Multiparametric Magnetic Resonance Imaging Program Implementation and Impact: Initial Clinical Experience in a Community Based Health System , 2017, Urology practice.

[33]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[34]  J. Gore,et al.  PSA SCREENING, PROSTATE BIOPSY, AND TREATMENT OF PROSTATE CANCER IN THE YEARS SURROUNDING THE USPSTF RECOMMENDATION AGAINST PROSTATE CANCER SCREENING: PD43‐12 , 2017 .

[35]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[36]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study , 2017, The Lancet.

[37]  Antonio Alcaraz,et al.  Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. , 2017, The Lancet. Oncology.

[38]  Geert Trooskens,et al.  Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. , 2016, European urology.

[39]  F. Montorsi,et al.  The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers. , 2016, European urology.

[40]  J. Hugosson,et al.  Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial. , 2016, European urology.

[41]  A. Kibel,et al.  Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Eeles,et al.  The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer , 2016, The oncologist.

[43]  Jonathan E. Shoag,et al.  Reevaluating PSA Testing Rates in the PLCO Trial. , 2016, The New England journal of medicine.

[44]  P. Scardino,et al.  The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. , 2016, Urology.

[45]  Tristan Barrett,et al.  Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI‐transrectal ultrasonography (TRUS) fusion‐guided transperineal prostate biopsies as a validation tool , 2016, BJU international.

[46]  Martin Eklund,et al.  Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. , 2015, The Lancet. Oncology.

[47]  J. Fütterer,et al.  Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. , 2015, European urology.

[48]  A. Jemal,et al.  Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. , 2015, JAMA.

[49]  J. Hugosson,et al.  Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. , 2015, European urology.

[50]  S. Taneja,et al.  Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data. , 2015, The Journal of urology.

[51]  S. Eggener,et al.  National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  P. Sasieni,et al.  Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  P. Prorok,et al.  Conceptualizing overdiagnosis in cancer screening. , 2015, Journal of the National Cancer Institute.

[54]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  W. Lowrance,et al.  Prostate cancer risk prediction based on complete prostate cancer family history , 2014, The Prostate.

[56]  L. Kiemeney,et al.  Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study , 2014, European urology.

[57]  A. Vickers,et al.  Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. , 2014, The Journal of urology.

[58]  T. Tammela,et al.  Overdiagnosis and overtreatment of prostate cancer. , 2014, European Urology.

[59]  S. Eggener,et al.  National trends in prostate cancer screening among older American men with limited 9‐year life expectancies: Evidence of an increased need for shared decision making , 2014, Cancer.

[60]  Andrew J Vickers,et al.  Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen , 2014, BMC Medicine.

[61]  G. Kristiansen,et al.  Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial. , 2013, European urology.

[62]  Walter Artibani,et al.  Early detection of prostate cancer: European Association of Urology recommendation. , 2013, European urology.

[63]  Mohammad Hassan Murad,et al.  Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[64]  P. Scardino,et al.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study , 2013, BMJ : British Medical Journal.

[65]  H. D. de Koning,et al.  Quality-of-life effects of prostate-specific antigen screening. , 2012, The New England journal of medicine.

[66]  L. Holmberg,et al.  Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. , 2012, European urology.

[67]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[68]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[69]  F. Montorsi,et al.  Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. , 2011, European urology.

[70]  P. Scardino,et al.  Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate‐specific antigen at or before age 50 , 2011, Cancer.

[71]  Andrew J Vickers,et al.  Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  D. Howard.  Life expectancy and the value of early detection. , 2005, Journal of health economics.

[73]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[74]  A. Pantuck,et al.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. , 1992, The Journal of urology.

[75]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[76]  T. Huebner,et al.  Prostate Biopsy Characteristics: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Guidelines. , 2018, Reviews in urology.

[77]  M. Roobol,et al.  The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA , 2017, Nature Reviews Urology.

[78]  A. Vickers,et al.  Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study. , 2017, European urology.

[79]  P. Scardino,et al.  Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results. , 2017, Reviews in urology.

[80]  A. Rosenkrantz,et al.  Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy. , 2017, Urology.

[81]  Any Psa,et al.  Variation Among Primary Care Physicians in Prostate-Specific Antigen Screening of Older Men , 2016 .

[82]  A. Auvinen,et al.  Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. , 2015, Journal of the National Cancer Institute.

[83]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[84]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.